.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 9,149,532

« Back to Dashboard

Claims for Patent: 9,149,532

Title:Pharmaceutical composition
Abstract: To provide pharmaceutical preparation exhibiting satisfactory dissolution property in a wide pH range. The pharmaceutical composition is characterized by containing (A) N.sup.1-(5-chloropyridin-2-yl)-N.sup.2-((1S,2R,4S)-4-[(dimethylamino)carb- onyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl- ]amino}cyclohexyl)ethanediamide, represented by the following formula (1), a pharmacologically acceptable salt thereof, or a hydrate of any of these, and (B) one or more species selected from the group consisting of a sugar alcohol and a water-swelling additive. ##STR00001##
Inventor(s): Kojima; Masazumi (Shinagawa-ku, JP), Kuno; Yoshio (Shinagawa-ku, JP), Nakagami; Hiroaki (Shinagawa-ku, JP), Sagasaki; Shinji (Shimada, JP), Ishidoh; Koichi (Hiratsuka, JP), Sekiguchi; Gaku (Hiratsuka, JP)
Assignee: Daiichi Sanykyo Company, Limited (Tokyo, JP)
Application Number:13/968,776
Patent Claims: 1. A pharmaceutical composition in the form of a tablet wherein the tablet comprises: (A) N'-(5-chloropyridin-2-yl)-N.sup.2-((1S,2R,4S)-4-[(dimethylamino)carbonyl]- -2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amin- o}cyclohexyl)ethanediamide, represented by formula (1): ##STR00005## pharmacologically acceptable salt thereof, or a hydrate thereof; (B) a sugar alcohol that is one or more species selected from the group consisting of mannitol, xylitol, and erythritol, wherein the sugar alcohol is present in an amount from 40 to 60 wt. % with respect to the total weight of the pharmaceutical composition; and (C) a water-swelling additive selected from pregelatinized starch, crystalline cellulose or a combination thereof; wherein the ratio of sugar alcohol to water-swelling additive is 1.5 to 4 parts by weight sugar alcohol to 1 part by weight water-swelling additive; and wherein the tablet is coated with at least one coating agent selected from the group consisting of hypomellose, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, and polyvinyl alcohol, and wherein the coating agent is present in the amount of 1.5 to 5 wt. % with respect to the total weight of the pharmaceutical composition.

2. The pharmaceutical composition according to claim 1, wherein the sugar alcohol is mannitol.

3. The pharmaceutical composition according to claim 1, wherein the water-swelling additive is pregelatinized starch.

4. The pharmaceutical composition according to claim 1, wherein the coating agent is one or more species selected from the group consisting of hypromellose, ethyl cellulose, and polyvinyl alcohol.

5. The pharmaceutical composition according to claim 1, wherein the coating agent is hypromellose.

6. The pharmaceutical composition according to claim 1, wherein the compound represented by formula (1), a pharmacologically acceptable salt thereof, or a hydrate of any of these is N.sup.1-(5-chloropyridin-2-yl)-N.sup.2-((1S,2R,4S)-4-[(dimethylamino)carb- onyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl- ]amino}cyclohexyl)ethanediamide hydrochloride.

7. The pharmaceutical composition according to claim 1, wherein the compound represented by formula (1), a pharmacologically acceptable salt thereof, or a hydrate thereof is N.sup.1-(5-chloropyridin-2-yl)-N.sup.2-((1 S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothia- zolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide p-toluenesulfonate monohydrate.

8. The pharmaceutical composition according to claim 1, wherein the compound represented by the formula (I) is present in an amount of 12 to 25 wt. % with respect to the total weight of the pharmaceutical composition.

9. The pharmaceutical composition according to claim 1, wherein the water-swelling additive is present in an amount of 10 to 30 wt. % with respect to the total weight of the pharmaceutical composition.

10. The pharmaceutical composition according to claim 1, wherein the coating agent is present in an amount of 2-5 wt. % with respect to the total weight of the pharmaceutical composition.

11. The pharmaceutical composition according to claim 1, wherein the compound represented by the formula (I) is present in an amount of 15 to 60 wt. % with respect to the total weight of the pharmaceutical composition.

12. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition exhibits an average percent dissolution of the compound represented by the formula (I) in a dissolution test medium having a pH of 6.8 of 60% or higher in 30 minutes after the start of the dissolution test and 70% or higher in 60 minutes after the start of the dissolution test when the pharmaceutical composition is subjected to a dissolution test by a paddle method at a rotation of 50 rpm.

13. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition exhibits an average percent dissolution of the compound represented by the formula (I) in a dissolution test medium having a pH of 6.8 of 70% or higher in 30 minutes after the start of the dissolution test and 80% or higher in 60 minutes after the start of the dissolution test when the pharmaceutical composition is subjected to a dissolution test by a paddle method at a rotation of 50 rpm.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc